NASDAQ · MLYS
Healthcare · Biotechnology
$31.12
Up+$2.91 (+10.32%)
Updated Sep 9, 2026, 2:53 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MLYS closed at $31.12 after 20 trading sessions, up 13.87% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 8, 2026 | $28.03 | $31.59 | $28.03 | $31.12 | 2.59M |
| Sep 4, 2026 | $28.00 | $28.35 | $27.395 | $28.21 | 643.52K |
| Sep 3, 2026 | $29.15 | $29.40 | $27.715 | $28.27 | 1.33M |
| Sep 2, 2026 | $25.70 | $29.285 | $25.70 | $29.04 | 2.04M |
| Sep 1, 2026 | $25.47 | $26.33 | $24.98 | $25.57 | 728.42K |
| Aug 31, 2026 | $25.42 | $25.95 | $25.06 | $25.67 | 1.08M |
| Aug 28, 2026 | $25.81 | $26.105 | $25.25 | $25.60 | 812.83K |
| Aug 27, 2026 | $25.86 | $26.24 | $25.53 | $26.01 | 420.75K |
| Aug 26, 2026 | $26.30 | $26.30 | $25.57 | $25.89 | 766.39K |
| Aug 25, 2026 | $25.47 | $26.665 | $25.375 | $26.34 | 863.97K |
| Aug 24, 2026 | $25.68 | $25.86 | $24.95 | $25.27 | 591.2K |
| Aug 21, 2026 | $25.97 | $26.3999 | $25.63 | $25.65 | 699.84K |
| Aug 20, 2026 | $26.53 | $26.62 | $25.30 | $25.75 | 785.19K |
| Aug 19, 2026 | $27.46 | $27.75 | $26.695 | $26.95 | 1.22M |
| Aug 18, 2026 | $25.90 | $26.89 | $25.75 | $26.61 | 1.1M |
| Aug 17, 2026 | $25.46 | $26.10 | $25.00 | $26.05 | 802.25K |
| Aug 14, 2026 | $25.88 | $25.885 | $25.42 | $25.64 | 697.76K |
| Aug 13, 2026 | $27.13 | $27.13 | $25.91 | $26.09 | 863.23K |
| Aug 12, 2026 | $25.12 | $27.80 | $25.10 | $27.05 | 1.4M |
| Aug 11, 2026 | $27.57 | $27.57 | $26.62 | $27.33 | 679.8K |
The latest Smart Investors Daily articles mentioning MLYS.
MLYS research
Company profile and research snapshot.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 27, 2026 | TD Cowen | Buy | — |
| Mar 13, 2026 | B of A Securities | Buy | — |
| Dec 19, 2025 | Stifel | Buy | — |
| Nov 12, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 11, 2025 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Aug 27, 2026
abrdn Healthcare Opportunities Fund upgraded: 10.9% yield, -4.5% NAV discount, good distribution coverage and healthcare rebound potential. Click for a THQ update.
Yahoo · Aug 26, 2026
RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 202
SeekingAlpha · Aug 12, 2026
Yahoo · Jul 3, 2026
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 8 Hidden Multibagger Stocks to Buy Now. During the last few trading sessions, Mineralys Therapeutics Inc. (NASDAQ:MLYS) has seen positive momentum. On June 4, Goldman Sachs analyst Richard Law reiterated a Buy rating on the stock and assigned a target price of $42. Earlier on June 2, […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MLYS.
